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Mucus hypersecretion is a prominent feature of respiratory
diseases, and MUC5B is a major airway mucin. Mucin gene
expression can be affected by inflammatory mediators, includ-
ing prostaglandin (PG) D2, an inflammatory mediator synthe-
sized by hematopoietic PGD synthase (H-PGDS). PGD2 binds to
either D-prostanoid receptor (DP1) or chemoattractant receptor
homologous molecule expressed on T-helper type 2 cells
(CRTH2). We investigated the mechanisms by which PGD2
induces MUC5B gene expression in airway epithelial cells.
Western blot analysis showed that H-PGDS was highly
expressed in nasal polyps. Similar results were obtained for
PGD2 expression. In addition, we could clearly detect the
expressions of both H-PGDS and DP1 in nasal epithelial cells
but not CRTH2. We demonstrated that PGD2 increased
MUC5B gene expression in normal human nasal epithelial cells
as well as in NCI-H292 cells in vitro. S5751, a DP1 antagonist,
inhibited PGD2-inducedMUC5B expression, whereas a CRTH2
antagonist (OC0459) did not. These data suggest that PGD2
inducedMUC5B expression via DP1. Pretreatment with extra-
cellular signal-regulated kinase (ERK) inhibitor (PD98059)
blocked both PGD2-induced ERK mitogen-activated protein
kinase (MAPK) activation and MUC5B expression. Proximity
ligation assays showed direct interaction between RSK1 and
cAMP response element-binding protein (CREB). Stimula-
tion with PGD2 caused an increase in intracellular cAMP lev-
els, whereas intracellular Ca2 did not have such an effect.
PGD2-inducedMUC5BmRNA levels were regulated by CREB
via direct interaction with two cAMP-response element sites
(921/914 and900/893). Finally, we demonstrated that
PGD2 can induce MUC5B overproduction via ERK MAPK/
RSK1/CREB signaling and that DP1 receptor may have sup-
pressive effects in controllingMUC5B overproduction in the
airway.
Mucus secretion in the airway, including the nasal and parana-
sal sinus cavities, is drained by the mucociliary transport system
(1). Normal mucus secretion is essential for survival (2), but up-
regulation of mucin gene expression is a major manifestation of
chronic airway diseases such as allergic rhinitis, asthma, and cystic
fibrosis (3, 4). Patients suffering from these diseases have patho-
logical abnormalities in both the submucosal glands and surface
epithelium, characterized by inflammation, increased mucus cell
number, and increasedairwaymucus. Several classesof inflamma-
tory mediators have been implicated in the process of mucus
hypersecretion based on their ability to stimulate secretion from
cultured cells and tissue explants (5). These inflammatory media-
tors are lipopolysaccharides (6), reactive oxygen species (7), and
arachidonic acid metabolites (8, 9).
A total of 20 different mucin genes have been identified and
subdivided into two groups, membrane-bound and secreted
mucins, according toHumanGenomeMappingconventions.The
secreted mucins are MUC5AC, MUC5B, MUC6, and MUC19
(10–13). Mucins are primarily synthesized by two different cell
types in theairway tract, namely, goblet cells andsubmucosal glan-
dular cells. The major secreted mucins, MUC5AC and MUC5B,
arehighlyexpressed in thegoblet cellsofhumanairwayepithelium
and in the submucosal glands (14). Interestingly, differences in cell
type-specificMUC5B gene expression are significantly associated
with the pathogenesis of airway diseases (15), although little is
known about the regulation of this gene.
Prostaglandins (PGs)2 are potent biologically active lipid
mediators that are produced from arachidonic acid by almost
* This work was supported by the Basic Science Research Program through
the National Research Foundation of Korea funded by theMinistry of Edu-
cation, Science, and Technology (2011-0001168).
1 Towhom correspondence should be addressed: Dept. of Otorhinolaryngol-
ogy, Yonsei University College of Medicine, 134 Shinchon-dong, Seodae-
mun-gu, Seoul, 120-752, Korea. Tel.: 82-2-2228-3610; Fax: 82-2-393-0580;
E-mail: jhyoon@yuhs.ac.
2 The abbreviations used are: PGD2, prostaglandin (PG) D2; H-PGDS, hemato-
poietic prostaglandinD synthase; DP1, D-prostanoid receptor; CRTH2, che-
moattractant receptor homologous molecule expressed on T-helper type
2 cells; RSK1, p90 ribosomal S6 protein kinase 1; CRE, cAMP-response ele-
ment; CREB, CRE-binding protein; FAM, carboxyfluorescein; TAMARA, car-
boxytetramethylrhodamine; 2M, 2-microglobulin; PLA, proximity liga-
tion assay; NHNE, normal human nasal epithelial.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 286, NO. 39, pp. 34199–34214, September 30, 2011
© 2011 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
SEPTEMBER 30, 2011•VOLUME 286•NUMBER 39 JOURNAL OF BIOLOGICAL CHEMISTRY 34199
 at Y
O
N
SEI U
N
IV
ERSITY
 on N
ovem
ber 13, 2013
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
every cell type (16) and are also known to regulate immune
responses (17). One of them, prostaglandin D2 (PGD2), is
thought to be involved in allergic reactions (18), and its actions
are mediated via specific cell surface receptors coupled to G
proteins, D prostanoid receptor 1 (DP1), and chemoattractant
receptor homologous molecules expressed on Th2 cells
(CRTH2/DP2) (19). Activation of DP receptor leads to a Gs-
mediated increase in intracellular cAMP and agonist-induced
Ca2 flux (20). Moreover, PGD2 signaling through CRTH2
coupledwith theGi-typeGprotein leads to a decrease in cAMP,
which subsequently stimulates intracellularCa2 in various cell
types (21). Because increases in intracellular Ca2 levels are
often associated with immune-cell activation, the chemotactic
effects of CRTH2 are in agreement with its reported signaling
pattern (22). There are two isoforms of PGD synthase in
the biosynthesis pathway. Hematopoietic PGD2 synthase
(H-PGDS) contributes to the production of PGD2 in antigen-
presenting cells and mast cells in diverse tissues (23, 24),
whereas lipocalin-type PGDS is generally expressed in the cen-
tral nervous system (25). In addition, it has been reported that
mouse models of allergic pulmonary inflammation suggest
an important pathogenetic role for PGD2 (26). Local antigen
challenge also stimulates PGD2 production in the nasal
mucosa of patients with allergic rhinitis (27). Thus, PGD2
seems to be an important chemical mediator in various aller-
gic diseases.
A better understanding of PGD2-mediated activation of air-
way epithelial cells is potentially important for establishing a
therapeutic strategy for allergic inflammation, but the precise
effects of PGD2 on airway epithelial cells and receptor usage are
not fully understood. In this study we investigated the mecha-
nisms by which PGD2 inducesMUC5B gene expression in air-
way epithelial cells. We found that the DP1 receptor played a
critical role in PGD2-induced MUC5B gene expression in the
airway. In addition, we observed that H-PGDS protein was
highly expressed in nasal polyps tissues comparedwith the level
in normal nasal mucosa. The level of PGD2 was also increased
in nasal polyp tissues in both allergic and non-allergic patients.
The DP1 receptor, but not the CRTH2-receptor, was highly
expressed in human primary nasal epithelial cells. Our results
showed a critical role of extracellular signal-regulated kinase
(ERK1/2) mitogen-activated protein kinase (MAPK) in PGD2-
inducedMUC5B gene expression in airway epithelial cells. Fur-
thermore, p90 ribosomal S6 protein kinase 1 (RSK1) and cAMP
response element (CRE)-binding protein (CREB) were found to
be required for PGD2-inducedMUC5B gene expression. Fluo-
rescent in situproximity ligation assays ofNCI-H292 cells dem-
onstrated that RSK1 can directly bind to CREB in the nucleus.
PGD2 did not directly induce an increase in intracellular Ca2
levels. In addition, analysis of the transcriptional activities of
MUC5B promoter regions showed that both CRE sites in the
MUC5B promoter (921/914 and 900/893) played an
essential role in PGD2-induced MUC5B gene expression.
Together these findings suggest new insights into themolecular
mechanisms by which PGD2 inducesMUC5B gene expression
in airway epithelial cells.
EXPERIMENTAL PROCEDURES
Materials—PGD2, the PGD2-MOX EIA kit, and anti-DP1
receptor rabbit polyclonal antibody were purchased from Cay-
man Chemical (Ann Arbor, MI). Forskolin and 3-isobutyl-1-
methylxanthine were purchased from Sigma. 8-Bromo-cAMP
was purchased from ENZO life science (Plymouth Meeting,
PA). S5751 (DP1-specific antagonist) and OC0459 (CRTH2-
specific antagonist) were obtained from TAIHO Pharmaceuti-
cal Co., Ltd (Saitama, Japan). PD98059 was purchased from
Calbiochem. Anti-prostaglandin D synthase murine monoclo-
nal antibody was obtained from Osaka Bioscience Institute.
Anti-CRTH2 goat polyclonal antibody and anti--actin mouse
monoclonal antibody were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA); anti-phospho-p44/42 MAP
kinase (Thr-202/Tyr-204), anti-p44/42 MAPK (ERK1/2), anti-
phospho-p38MAPK (Thr-180/Tyr-182), anti-phospho-SAPK/
JNK (Thr-183/Tyr-185), anti-SAPK/JNK, anti-phospho-RSK1
(Ser-380), anti-RSK1/2/3, anti-phospho-CREB (Ser-133), and
anti-CREB antibodies were purchased from Cell Signaling
Technology (Beverly, MA). siERK1 (catalogue number
sc-29307), siERK2 (catalogue number sc-35335), and negative
control small Interfering RNA (siRNA; catalogue number
sc-37007) were purchased from Santa Cruz Biotechnolo-
gy. siDP1 (GenBankTM accession number NM_000953) and
siCRTH2 (GenBankTM accession number NM_004778) were
synthesized by Bioneer (Daejeon, Korea). siRSK1 and siCREB
were synthesized by Invitrogen. An additional siRNA negative
control was also utilized (Stealth, catalogue number 12935–
300; Invitrogen). Fura-2 acetoxymethyl ester (Fura-2/AM) was
purchased from Teflabs (Austin, TX).
Cell Culture—Weobtainedwritten permission from subjects
and approval from the Institutional Review Board at Yonsei
University College of Medicine for the use of specimens. Nor-
mal human nasal epithelial (NHNE) cells were cultured as pre-
viously described (28, 29). In brief, epithelial cells from turbi-
nates were treatedwith 1%Pronase (TypeXIV protease, Sigma)
for 18–20 h at 4 °C. To remove fibroblasts, endothelial cells,
and myoepithelial cells, isolated cells were placed in a plastic
dish and cultured for 1 h at 37 °C. Isolated epithelial clusters
were divided into single cells through incubation with 0.25%
trypsin, EDTA. Passage-2 NHNE cells were seeded in 0.5 ml of
culture medium onto 24.5-mm, 0.45-m pore size Transwell
clear (Costar) culture inserts. Cells were cultured in a 1:1 mix-
ture of bronchial epithelial cell growth medium (Clonetics):
Dulbecco’s modified Eagle’s medium (Invitrogen) containing
all listed supplements as previously described (28). Cultures
were grown while submerged, and the culture medium was
changed on the first day and every other day thereafter. The
human lung mucoepidermoid carcinoma cell line NCI-H292
was purchased from the American Type Culture Collection
(catalogue number CRL-1848, Manassas, VA) and cultured in
RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine
serum (Invitrogen) in the presence of penicillin-streptomycin
at 37 °C in a 5% CO2-humidified chamber.
Western Blot Analysis—Nasal polyps were homogenized in
cell extraction buffer (Invitrogen). NCI-H292 cells were grown
to confluence in six-well plates. After treatment with 1 M
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PGD2, cells were lysed with cell extraction buffer (Invitrogen),
and the total amount of protein was quantitated using the
Pierce BCA Protein Assay kit (Thermo Rad Laboratories, Her-
cules, CA). Equal amounts of total protein (25 g) were
resolved via 10% SDS-polyacrylamide gel electrophoresis fol-
lowed by electrophoretic transfer to a polyvinylidene difluoride
membrane (PVDF, Immobilon; Millipore Corp., Bedford, MA)
at 250 mA for 90 min at 4 °C. The PVDF membrane was then
blocked with 5% skimmilk in Tris-buffered saline (TBS, 50 mM
Tris-Cl, pH 7.5, 150 mM NaCl) for 2 h at room temperature
followed by overnight incubation with primary antibodies in
TBST (0.5% Tween 20 in TBS). The membrane was washed
with 1TBST for 10min and then probed for 2 h with second-
ary antibodies conjugated to horseradish peroxidase. The
membrane was exposed to high performance autoradiography
film (Fuji XR film, Fuji FilmCorp., Tokyo, Japan) and visualized
using the ECL system (Santa Cruz, CA).
RNA Extraction and RT-PCR Analysis—Total cellular RNA
was extracted from NCI-H292 cells using RNA TRIzol reagent
(Invitrogen) according to the manufacturer’s protocol. The
extractedRNAwas treatedwith amplification grade deoxyribo-
nuclease I (Invitrogen) before cDNA synthesis. DNase I-treated
RNA (3g) was converted to cDNAwith the addition of Gene-
Amp RNA PCR kit components (Moloney murine leukemia
virus reverse transcriptase, RNase inhibitor, and random hexa-
mers; Applied Biosystems Inc., NJ) in a total volume of 25 l.
After reverse transcription, RT-PCR was performed using a
MyCyclerTM thermal cycler system (Bio-Rad) for 35 cycles
using previously described amplification conditions (30). All
PCR primers were synthesized by Bioneer. The primer
sequences were as follows:MUC5B forward (5-GCTGCTGC-
TACTCCTGTGAGG-3 (and reverse (5-AGGTGATGTT-
GACCTCGGTCTC-3); 2-microglobulin (2M) forward (5-
TCGCGCTACTCTCTCTTTCT-3) and reverse (5-GCT-
TACATGTCTCGATCCCACTTAA-3). The PCR products
were visualized using 2% agarose gel electrophoresis and
ethidium bromide staining.
Real-time PCR Analysis—Primers and probes were designed
using the Perkin Elmer Life Science Primer Express software
purchased from PE Biosystems (Foster City, CA). Real-time
RT-PCR was performed in a 96-well format using the PE Bio-
systems ABI PRISM 7300 sequence detection system (Foster
City, CA) with TaqMan Universal PCR master mix (Applied
Biosystems, Branchburg, NJ) and according to the conditions
recommended in the manufacturer’s protocol. Reactions were
performed in a final volume of 25 l containing 3 g of cDNA
(reverse transcription mixture), oligonucleotide primers at a
final concentration of 800 nM, and 200 nM TaqMan hybridiza-
tion probe. The probe for real-time PCR was labeled with car-
boxyfluorescein (FAM) at the 5-end and with the quencher
carboxytetramethylrhodamine (TAMARA) at the 3-end. The
following primers and probes were used:MUC5B forward (5-
TCTACCTGGACAACCACTACTGC-3) and reverse (5-
TGGTG ACAGTGAGGACGATATCC-3) and TaqMan
probe (FAM-CTGCCACTGCCGCTGCCGCC-TAMARA).
2Mendogenouscontrol reagentswere includedasnormalcon-
trols with the following primers and probes: 2M forward
(5-CGCTCCGTGGCCTTAGC-3) and reverse (5-GAG-
TACGCTGGATAGCCTCCA-3) and TaqMan probe (FAM-
TGCTCGCGCTACTCTCTCTTTCTGGC-TAMARA). Samples
were analyzed in triplicate using PCR with an initial 10-min
denaturation at 95 °C followed by 40 cycles of 15 s at 95 °C
and 1 min at 60 °C. The relative quantity of MUC5B mRNA
was determined using a comparative threshold method, and
the results were normalized against 2M as an internal
control.
Immunohistochemistry and Double Immunocytofluorescence
Staining—We performed immunohistochemical staining for
human hematopoietic-type prostaglandin D synthase (Osaka
Bioscience Institute, Japan). Paraffin-embedded sections (4
mm) were de-paraffinized and hydrated using standard proto-
cols, and antigen retrieval was performed by heating a slide-
mounted section in a microwave oven in 0.01 M sodium citrate
buffer, pH 6.0. The slide was then cooled to room temperature
and washed with 0.01 M phosphate-buffered saline (PBS). Non-
specific endogenous peroxidase activity was blocked via treat-
ment with 3% hydrogen peroxidase for 10 min. After washing,
sections were incubated overnight with the primary antibodies
at 4 °C. Negative controls were stained with purified mouse
non-immune IgG at the same concentration as the primary
antibody. Biotinylated link antibody and streptavidin/peroxi-
dase were applied for 10min followed by the addition of a solu-
tion of diaminobenzidine (Dako Corp., Carpinteria, CA) as a
substrate chromogen. Finally, the sectionswere lightly counter-
stained with hematoxylin/eosin and then mounted.
For double immunocytofluorescence staining, cells were
washed three times with PBS and treated with 1% Pronase
(Type XIV protease, Sigma) for 18–20 h at 4 °C. The cells were
then washed with PBS and separated into single cells by incu-
bation in 0.05% trypsin/EDTA. Next, the cells were washed
with PBS, and 200 l of the cell suspension (1  104 cells/ml)
was added to a slide funnel and fixed in cold methanol-acetone
solution for 5min. The slideswerewashed 3 timeswith PBS and
then blocked with blocking solution (10% normal goat serum,
Jackson ImmunoResearch Laboratories Inc., West Grove, PA)
for 1 h. The cells were thenwashedwith PBS and permeabilized
in 0.1% Triton X-100, PBS for 20 min. MUC5AC protein was
detected using the MUC5AC monoclonal antibody (1:100,
Santa Cruz). Prostaglandin D2 receptor proteins were detected
via incubation with the DP1 rabbit polyclonal antibody (1:100,
Cayman Chemical, CA) and CRTH2 goat polyclonal antibody
(1:100, Santa Cruz Biotechnology) for 24 h at 4 °C followed by
several washes in PBS. Incubation was repeated with an appro-
priate fluorescein isothiocyanate and Texas Red-conjugated
secondary antibody (1:100, Jackson ImmunoResearch), and cell
nuclei were stainedwith 4,6-diamidino-2-phenylindole. Cover-
slips were mounted onto slides with Vectashield Mounting
Medium (Vector Laboratories, Inc., Burlingame, CA) and
examined using a Zeiss LSM 510 confocal microscope (Carl
Zeiss, Inc.).
Measurement of PGD2 Levels—Tissues (nasal polyps, nasal
mucosa) were homogenized in ice-coldmethanol (MeOH), and
the resulting homogenate was incubated for about 30 min on
ice to extract the lipid fraction. The homogenate was centri-
fuged at 3000  g for 10 min at 4 °C, and the supernatant was
collected in new clean tubes. To collect any remainder of the
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lipid fraction, MeOH was added to the residue and vortexed
thoroughly. The precipitated proteins were removed via cen-
trifugation, and the supernatant was evaporated to dryness
under nitrogen (N2). PGD2 in the residue was derivatized to
PGD2-methoxime. Next, the homogenate was centrifuged at
3000 g for 10min at 4 °C, after which the combined superna-
tant was concentrated at reduced pressure under N2 with cen-
trifugation.Next, the dried residuewas dissolved in ice-cold 1M
acetate buffer, pH  4.0. Purification of arachidonic acid
metabolite was performed with an SPE C18 cartridge (Sep-Pak
C18 Vac, Cayman Chemicals). The eluted fraction was concen-
trated at reduced pressure under N2 via centrifugation. The
dried residue was dissolved in ice-cold EIA buffer (included
with the EIA kit). Concentrations of PGD2 in the purified sam-
ples were quantified using a prostaglandin D2-Mox enzyme
immunoassay kit according to the manufacturer’s directions
(Cayman Chemical).
Measurement of MUC5B Concentrations—Enzyme-linked
immunosorbent assay (ELISA) was used to determine the
MUC5B protein levels. Cell lysates from humanNCI-H292 air-
way epithelial cells and NHNE were prepared in phosphate-
buffered saline (PBS). In brief, the cells were then washed three
times with cold PBS. Cells were collected after adherent cells
were digested by trypsin and then centrifuged. The homoge-
nate was centrifuged at 5000  g for 5 min at 4 °C, and the
supernatant was then collected in new clean tubes. Then phys-
ical methods for cell cleavage were undertaken (cells were son-
icated, then repeatedly frozen and thawed). Next, the homoge-
nates were centrifuged for 5 min at 5000  g, and the
supernatant was collected in new tubes. Concentrations of
MUC5B levels in the samples were quantified using a MUC5B
enzyme immunoassay kit according to the manufacturer’s
directions (Uscn Life Science Inc.). The absorbance was read at
450 nm.
Transient Transfection and Luciferase Analysis—MUC5B
gene constructs containing promoter deletions and CRE site
pointmutationswere reported in our previous study (30). Dele-
tion mutants covering the promoter regions of MUC5B were
generated through PCR (30). NCI-H292 cells were seeded
(2.5 105 cells/well) in six-well tissue culture plates with plas-
mid DNA (1 g/well) 24 h before transfection using FuGENE6
TransfectionReagent (RocheApplied Science) according to the
manufacturer’s recommendations. After transfection, cells
were maintained in RPMI media containing 0.2% serum for
24 h before treatment with 1 M PGD2. Cells were harvested
24 h after treatment and assayed for luciferase activity using a
dual-luciferase reporter assay system (Promega, Madison, WI)
in which the activity value was normalized to that of a -galac-
tosidase expression vector. Luciferase activity in cell extracts
(20 l) was measured on a Berthold 9501 luminometer using
luciferase assay reagent. Each plasmid was assayed in duplicate
in at least three separate experiments. To confirm that the lucif-
erase activity of each construct was induced by PGD2, the activ-
ity of each construct was alsomeasured in the absence of PGD2.
siRNA Treatment—Cells were plated in 6-well plates 24 h
before transfection with siERK1/2, siRSK1, siCREB, and nega-
tive control siRNA using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. After transfec-
tion, cells were maintained in 0.2% serum RPMI media for
16–18 h before treatment with PGD2 and then harvested. The
efficiency of siRNA knockdownwas determined usingWestern
blot analysis with the relevant antibodies.
cAMP Detection Assay—NCI-H292 cells were plated in
6-well plates 1 day before treatment. Cells were incubated with
DMSO or PGD2 for various times at 37 °C. 3-Isobutyl-1-meth-
ylxanthine (1mM)was added to the culture 10min before treat-
ment to prevent degradation of cAMP. Cells were then lysed
through three rounds of freezing and thawing and centrifuged
at 10,000 g for 10min. Supernatants were then collected, and
cAMP concentrations were determined using a cAMP detec-
tion kit according to the manufacturer’s protocol (Cayman
Chemical).
Measurement of Calcium Ion Concentration—NCI-H292
cells were seeded onto glass coverslips in 35-mm dishes (2.5
105 cells/coverslip) and cultured for 1 day. The cells were incu-
bated with 5 M Fura-2/AM for 40 min at room temperature
and washed with bath solution (140 mMNaCl, 5 mM KCl, 1 mM
MgCl2, 10 mM HEPES, 1 mM CaCl2, 10 mM glucose, 310 mosM,
pH 7.4). The coverslips were transferred to a perfusion cham-
ber, and the cells were continuously perfused with prewarmed
(37 °C) bath solution. Fura-2-AM-loaded cells were mounted
onto the stage of an invertedmicroscope (Nikon, Tokyo, Japan)
for imaging. The cells were illuminated at 340 and 380 nm, and
the emitted fluorescent images at 510 nmwere collected with a
CCD camera. The images were digitized and analyzed using the
MetaFluor system (Universal Imaging Co., Downingtown, PA).
The fluorescence ratio (340/380) was used as a measure of the
free calcium ion concentration [Ca2]i, and fluorescence
images were obtained at 3-s intervals.
Chromatin Immunoprecipitation (ChIP) Assay—For ChIP
assays, chromatin was isolated as previously described (31). In
brief,2 109 NCI-H292 cells in 150-mm dishes were treated
with PBS containing 1% formaldehyde for 10min and washed 3
timeswith ice-cold PBS.Cells were then harvested into PBS and
collected via centrifugation. The cells were resuspended in 1ml
of cell lysis buffer (5mMKOH, pH8.0/85mMKCl, 0.5%Nonidet
P-40) and incubated for 10min on ice. After a short spin (5min
at 5000 rpm), the pellets were resuspended in nuclear lysis solu-
tion (50 mM Tris, pH 8.1, 10 mM EDTA, 1% SDS) containing
protease inhibitors and sonicated to break the chromatin into
fragments with average lengths of 0.3 to 1.5 kb. After centrifug-
ing at 5000 rpm for 5min, the nuclear pellets were resuspended
in ChIP dilution buffer (1.2 mM EDTA, 16.7 mM Tris-HCl, pH
8.1, 0.01% SDS, 1.1% Triton X-100, 167 mM NaCl) containing
protease inhibitors. The assay used 2g of anti-phospho-CREB
(Ser-133) antibody and 2 g of rabbit IgG as a negative control.
Primers used for ChIP analysis included the following: CRE
(956 to 753), 5-ACGCGTGAGGTATTGCAGCGCG-
GACG-3, 5-GGTTGAGGAAGCAGCTGCTC-3; negative
controls (3960 to 3761, upstream of the CRE element; non-
CRE), 5-CCAGGCACTGGCTCTGAGA-3, 5-GAGGGT-
CCCATCGTGTGAC-3.
In Situ Proximity Ligation Assay—To detect the interaction
between CREB and RSK1, we utilized the DuoLinkTM in situ
proximity ligation assay (PLA) (Olink Bioscience, Uppsala,
Sweden) according to the manufacturer’s protocol. NCI-H292
PGD2 Up-regulatesMUC5B Gene Expression
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cells, cultured on glass coverslips, were rinsed with PBS and
fixed with 4% paraformaldehyde for 20 min at room tempera-
ture followed by a 10min of incubation with 0.1% Triton X-100
solution in PBS and an additional 30min of incubation in block-
ing solution. Cells were then immunolabeledwith primary anti-
bodies (1:100) for 1 h at 4 °C. A monoclonal antibody to CREB
(Santa Cruz Biotechnology) and polyclonal antibody (Cell Sig-
naling Technology) to RSK1 were used to detect protein-pro-
tein interactions under confocal microscopy at 60magnifica-
tion. The secondary antibodies with attached PLA probes were
supplied in the Duolink kit, and a fluorescence signal was mea-
sured to indicate that the two proteins were separated by 40
nm (Olink Bioscience).
Statistical Analysis—Quantified RT-PCR signals were nor-
malized to 2M levels and presented as the mean  S.D. Stu-
dent’s t test was used to determine the significances of differ-
ences in expression data. Statistical analysis was performed
using the programGraphPadPrism4 (GraphPadSoftware, Inc.,
La Jolla, CA). Differences were considered to be significant at
values less than p 0.05.
RESULTS
Both H-PGDS and PGD2 Proteins Are Highly Expressed in
Human Nasal Polyps—To determine whether H-PGDS is
expressed in human nasal polyp tissues, we first examined
H-PGDS expressions in normal nasal mucosa and nasal polyp
tissue using Western blot analysis. The expression of H-PGDS
in nasal polyp tissues was similar in patients from both allergic
and non-allergic groups; however, the expression in nasal polyp
tissues was significantly greater (more than 3-fold) than that in
nasal mucosa (Fig. 1A). A similar result was obtained for PGD2
expression (Fig. 1B). We showed that H-PGDS expression was
characteristic of nasal polyp tissues with a high secretion of
PGD2. Next, we used immunohistochemistry to investigate
whether H-PGDS was located in human nasal epithelial cells
(Fig. 1C) and found that H-PGDS was highly expressed
throughout the epithelium of nasal polyp tissue. These data
suggested that PGD2 plays an important role in the inflamma-
tion response. DP1 receptor but not CRTH2 receptor is highly
expressed in human primary nasal epithelial cells.
Next we investigated the cellular localization of PGD2 recep-
tors (DP1 and CRTH2) in human primary nasal epithelial cells
using double immunocytofluorescence staining.MUC5ACwas
used as a goblet cell marker (Fig. 2, red) (32), whereas DP1
(green staining) was detected on the surfaces of goblet cells as
yellow objects in the merged image, indicating double immu-
nofluorescence of DP1 and MUC5AC in both goblet and non-
goblet cells of human primary nasal epithelia. In contrast,
CRTH2 receptor was barely expressed. No staining was
detected in control experiments in which primary antibodies
against DP1, CRTH2, and MUC5AC were replaced with puri-
fied IgG (Fig. 2, upper panel).
PGD2 Induces MUC5B Expression in Both NHNE Cells and
Human Lung Mucoepidermoid Carcinoma (NCI-H292) Cells—
To determine whether PGD2 could induce mucin gene expres-
sion in NHNE and NCI-H292 cells, we performed real-time
quantitative PCR on cells that had been treated with various
concentrations of PGD2 (0.01, 0.1, and 1 M) for 24 h. The
mRNA levels of secretedmucin genes in the cell lysates, such as
MUC5B, 6, 8, and 5AC, were determined and compared using
RT-PCR (data not shown). Mucin gene expression was signifi-
cantly induced by 0.01 M PGD2. Interestingly, some secreted
mucin genes in NCI-H292 cells, such as MUC6, -8, and -5AC,
did not exhibit any increase due to PGD2 (data not shown).
However, one of the major secreted gel-forming mucin genes
(MUC5B) was increased in both cells (Fig. 3A, NHNE, greater
than 6-fold induction; Fig. 3B, NCI-H292 cells, greater than
2-fold induction). Because the characteristics of NCI-H292
cells were similar to those of NHNE cells, we used NCI-H292
cells in subsequent experiments.
To investigate whether PGD2 inducedMUC5B gene expres-
sion in a time-dependent manner, we performed RT-PCR after
treatingNCI-H292 cells with 1MPGD2 for various times (1, 3,
6, 12, and 24 h). We observed a time-dependent increase in
expression of MUC5B in NCI-H292 cells over a 24-h time
period (greater than 2-fold increase) (Fig. 3C).
Next, ELISA analysis was performed to investigate the effect
of PGD2 on MUC5B protein expression in airway epithelial
cells. We observed that PGD2 can induce MUC5B protein in a
dose-dependent manner in both cells (Figs. 3,D, NHNE, and E,
NCI-H292 cells; greater than 2-fold induction). These results
show that the MUC5B expression was increased at all PGD2
dose andpeaked at 1MPGD2 for 24 h.A concentration of 1M
PGD2 was used for all subsequent experiments.
PGD2-inducedMUC5B Gene Expression Is Dependent on the
DP1 Receptor in NCI-H292 Cells—To identify which PGD2
receptor was involved in PGD2-mediatedMUC5B gene expres-
sion, cells were treated for 24 h with the DP1 antagonist, S5751
(33, 34), or the CRTH2/DP2 antagonist, OC0459 (35). PGD2-
dependentMUC5B gene expression inNCI-H292 cells was sig-
nificantly inhibited by S5751 in a dose-dependent manner,
whereas OC0459 had very little effect (Fig. 4, A and B). The
increase in MUC5B gene expression by PGD2 treatment (2.2-
fold induction) was decreased by 20% (1.8-fold) and 47% (1.18-
fold) upon the addition of OC0459 and S5751, respectively.
These results suggest that the DP1 receptor likely mediates
PGD2-inducedMUC5B gene expression in NCI-H292 cells.
ERK1/2 Is Essential for PGD2-induced MUC5B Gene
Expression—To investigate which extracellular ERK MAPK
signaling pathway inNCI-H292 cells was activated by PGD2,we
performed Western blot analysis using specific antibodies.
Activation of ERK1/2 MAPK increased after 5 min of stimula-
tion with PGD2 and then gradually decreased (Fig. 5A). West-
ern blotting experiments indicated that p38MAPK and SAPK/
JNK (stress-activated protein kinase/Jun amino-terminal
kinase) were not activated by PGD2 treatment (Fig. 5A) and
thus did not appear to be involved in PGD2-induced MUC5B
gene expression. To further examine the role of ERK1/2 MAP
kinase, we pretreated cells with 30 M PD98059, an ERK1/2
inhibitor, for 1 h before treatment with PGD2 and subsequent
analysis of protein expression (Fig. 5C). PGD2 treatment signif-
icantly increased ERK1/2 activity, whereas pretreatment with
PD98059 completely attenuated the effect of PGD2. Moreover,
PD98059 completely inhibited PGD2-inducedMUC5BmRNA
expression (Fig. 5D). For further confirmation of these findings,
cells were transfected with siRNAs specific for ERK1 or ERK2
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MAPK. Interestingly, transfection with ERK1/2 siRNA specifi-
cally reduced PGD2-induced MUC5B gene expression com-
pared with the effects of control siRNA (Fig. 5F). These results
suggest that phosphorylation of ERK1/2 MAPK is required for
PGD2-inducedMUC5B gene expression in NCI-H292 cells.
DP1 Receptor Is Involved in PGD2-induced MUC5B
Expression—Next, we examined the role of PGD2 receptors in
the signal transduction pathway leading to MUC5B gene
expression in airway epithelial cells by transfecting NCI-H292
cells with 50 nM siRNA against DP1 or CRTH2. Cells were
treated with PGD2 24 h after transfection and subsequently
harvested for Western blot analysis. DP1 and CRTH2 siRNAs
suppressed intracellular DP1 andCRTH2mRNA levels inNCI-
H292 cells, respectively (data not shown). PGD2 treatment ini-
tially caused a 2.12-fold increase in MUC5B gene expression.
We found that the addition ofDP1 siRNAdecreased expression
by 48.0% (1.03-fold compared with 2.12-fold), whereas the
addition of CRTH2 siRNA only inhibitedMUC5B gene expres-
sion by 87.7% (1.86-fold compared with 2.12-fold) (Fig. 6B).
These results suggest that the DP1 receptor plays an important
role in PGD2-inducedMUC5B gene expression.
DP1-specific siRNA treatment also decreased the levels of
p-ERK1/2 (Fig. 6A), whereas CRTH2-specific siRNA had no
effect. These results indicated that DP1 receptor is an essential
mediator of ERK MAPK signaling for PGD2-induced MUC5B
expression in NCI-H292 cells.
PGD2-induced MUC5B Gene Expression Is Mediated by
RSK1—The p90 ribosomal S6 kinases (RSK) are a family of ser-
ine/threonine kinases that are activated downstream of the
Ras/MAPK pathway. RSK phosphorylates multiple signaling
FIGURE1.H-PGDSproteinandPGD2areexpressed inhumannasal polyps.A, the expressionofH-PGDS inhomogenates of tissue specimens from4healthy
subjects and 10 subjects with human nasal polyps is shown. Total cell lysates were prepared for Western blot analysis. Values above the figures represent the
relative density of the bands normalized to-actin. Results are representative of three independent experiments. Data are expressed as themean S.D. *, p
0.05 according to Wilcoxon’s rank sum test for control versus non-allergic group and control versus allergic group. B, we measured the PGD2 level in human
nasal polyps using a PGD2-MOX ELISA kit. PGD2 levels were standardized according to the concentration of total protein for each sample. Each bar represents
the median concentration of PGD2. Significance was determined by the Mann-Whitney U test. The results are expressed as pg/mg of protein and are the
mean S.D. of 4 healthy subjects and 10 subjects with nasal polyps. *, p 0.05 versus healthy subjects. **, p 0.05 versus healthy subjects. C, strong H-PGDS
immune-reactivity is observed in human primary nasal epithelial cells. The negative control (IgG; without H-PGDS antibody) shows no immunoreactivity
(200).
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effectors to play an essential role in a number of cellular func-
tions, including regulation of gene expression through the
phosphorylation of transcriptional regulators such as c-fos (36)
and CREB (37, 38). We found that phosphorylation of RSK1
peaked 30min after PGD2 stimulation and was decreased by 60
min (Fig. 7A). Densitometric analysis of Western blots showed
a significant increase in p-RSK1 at 30 min (Fig. 7B).
To determine whether RSK1 plays an important role in
PGD2-induced MUC5B gene expression, we performed an
RSK1 knockdown study. Cells were transfected with 40 nM
siRNA against RSK1 or a negative control siRNA and treated
with PGD2 24 h after transfection followed by harvesting for
Western blot analysis. RSK1-specific siRNA treatment
decreased the levels of p-RSK1 compared with the negative
siRNA control, which had no effect (Fig. 7C). Knockdown of
RSK1 led to an attenuation ofMUC5B gene expression accord-
ing to quantitative real-time RT-PCR (Fig. 7D). These results
suggest that PGD2-inducedMUC5B gene expressionwasmedi-
ated via phosphorylation of RSK1.
CREB but Not Ca2 Signaling Is Required for PGD2-induced
MUC5B Gene Expression—As RSK1 is a mediator of cytokine-
induced CREB phosphorylation at Ser-133 and CREB was pre-
viously shown to mediate the transcriptional regulation of
some mucins, we investigated whether CREB can be activated
by PGD2. Cells were treated with PGD2 for various times up to
1h followedbymeasurement ofCREBactivation throughphos-
phorylation monitoring of Ser-133 (p-CREB) inWestern blots.
As shown in Fig. 8A, PGD2 induced CREB activation in a time-
dependentmanner: The activation ofCREBwas observed 5min
after PGD2 treatment and was decreased at 30 min. Densito-
metric analysis of the Western blots showed a significant
increase in p-CREB at 10 min (Fig. 8B). To examine the func-
tion of activated CREB in transcriptional regulation of the
MUC5B gene by PGD2, CREB was knocked-down with RNAi.
Cells were treated with PGD2 24 h after transfection and har-
vested for Western blot analysis. As expected, CREB-specific
siRNA caused a reduction in the level of p-CREB. Furthermore,
CREB knockdown led to a decrease in the level ofMUC5B gene
expression as assessed by quantitative real-time RT-PCR (Fig.
8D).
Furthermore, it has been reported that RSKs can phosphor-
ylate CREB in the nucleus (39). To test if RSK1 can directly bind
to CREB inNCI-H292 cells, we performed an in situ PLA assay.
Cells were pretreated with PD98049 (ERK inhibitor) for 1 h
before treatment with PGD2.We observed that the PLA signals
visualizing RSK1 and CREB interactions were very low in non-
treated cells but were strongly induced by PGD2 treatment. In
contrast, reduction of the PLA signal (shown in red) indicated
that inhibition of ERK greatly attenuated the interaction of
RSK1 with CREB. This result suggests that RSK1 can bind to
CREB directly, and significant downstream mediators of ERK
MAPK signaling in PGD2 induced MUC5B gene expression
(Fig. 8E).
DP1 is coupled to the G-protein subunit, Gs, the activation
of which results in elevated intracellular cAMP levels. If the
effects of PGD2 on airway epithelial cells are mediated via DP1
signaling, PGD2 treatment of cells should result in increased
intracellular cAMP levels compared with those in the controls.
Indeed, we found that PGD2 treatment increased cAMP levels
in NCI-H292 cells, peaking within 10 min of incubation and
then decreasing over at least 30 min (Fig. 8F).
Binding of PGD2 to the DP1 receptor has also been shown to
elicit an increase in the concentration of intracellular Ca2 in
certain cell types (40). Next, we tested the ability of PGD2 to
mobilize Ca2 in airway epithelial cells. As shown in Fig. 8G,
PGD2-treated cells failed to induce a significant Ca2 influx in
NCI-H292 cells. In addition, therewas no change inCa2 influx
when the cells were treated with forskolin either in the absence
or presence of 3-isobutyl-1-methylxanthine (data not shown).
Another study has reported that intracellular Ca2 is
dependent on CREB (41). In our study, PGD2 treatment did not
directly trigger any significant increase in the intracellular Ca2
concentration in NCI-H292 cells despite the involvement of
CREB in PGD2-induced MUC5B gene expression. We also
examined the effect of PGD2 on [Ca2]i in A549 and BEAS-2B
cells and obtained similar results (data not shown). These find-
ings provide evidence that CREB plays an important role in
PGD2-inducedMUC5B gene expression, althoughCa2 signal-
ing is not involved in this process.
ERKMAPK Signaling Is Required for Transcriptional Activa-
tion of PGD2-induced MUC5B Gene via Recruitment for Phos-
pho-CREB on the CRE of MUC5B Gene—Our previous data
showed that PGD2 induced CREB phosphorylation and CREB-
dependent MUC5B transcription in NCI-H292 cells. To iden-
tify the PGD2-responsive region in theMUC5B promoter, cells
were transiently transfected with MUC5B deletion mutants
and treated with PGD2 for 24 h. We had already constructed
multiple MUC5B promoter deletions in previous studies (30,
42). As shown in Fig. 9A, PGD2-induced luciferase activities of
the 2140/92, 1329/92, and 956/92 regions of the
MUC5B promoter (2.2-fold) were enhanced compared with
those in the530/92 regions, which indicates that the956/
FIGURE 2. PGD2 receptors are expressed in human primary nasal epithe-
lial cells. Cellular localization of PGD2 receptors (DP1 and CRTH2) and
MUC5AC proteins in human nasal epithelial cells was analyzed using double-
immunocytofluorescence staining with antibodies against MUC5AC and
PGD2 receptors (DP1 and CRTH2). Immunostaining of MUC5AC (red) and DP1
(green) is shown.Merged images show co-localization ofMUC5AC andDP1 in
yellow (middle panels). ImmunostainingofMUC5AC (red) andCRTH2 (green) is
shown.Overlays of the images showco-localizationofMUC5ACandCRTH2 in
yellow (lower panels). No staining was detected when both primary antibod-
ies were omitted (upper panels) (Bars indicate 10 m).
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530 region of the MUC5B promoter may be critical for the
response to PGD2.
The CREB pathway may directly affect PGD2-induced tran-
scriptional activation of the MUC5B gene if the two CRE sites
within the 956/530 region of the MUC5B promoter (5-
TGACGCTG-3 at 921/914 and 5-TGACGCTC-3 at
900/893) act as cis elements. We, therefore, investigated
whether CRE activation was required for PGD2-induced
MUC5B transcription by performing site-directedmutagenesis
of theCREB-binding site (Fig. 9B). BothCREmutant constructs
M1 andM2 showed decreasedMUC5B transcriptional activity
compared with that of the wild type (Fig. 9B), suggesting that
both CRE sites in the regulatory region of the MUC5B pro-
moter were involved in the PGD2-dependent up-regulation of
MUC5B transcriptional activity.
We further confirmed this conclusion via ChIP assay. To this
end, cells were first treated with or without PGD2 for 20 min
and processed for ChIP using anti-phospho-CREB and anti-
CREB antibodies. Because the region from956 to753 con-
tains putative CRE binding sites, we performed ChIP assays
using specific primers (956/753) for PCR.We also used the
region 3960/3761 as a negative control. After purification
FIGURE 3. PGD2 induces MUC5B expression in NHNE and human lung mucoepidermoid carcinoma (NCI-H292) cells. A, NHNE cells were pretreated
apically and basolaterally with PGD2 at the indicated concentrations for 24 h. Cell lysates were harvested for real-time quantitative RT-PCR. B, NCI-H292 cells
were treatedwith PGD2 (0.01, 0.1, and 1M) for 24 h. Cell lysates were harvested for real-time quantitative RT-PCR. C, cells were treatedwith PGD2 (1M) for 1,
3, 6, 12, and 24 h, and total RNAwere isolated.MUC5B expression relative to that of2Mwas determined using real-time quantitative RT-PCR.D, wemeasured
MUC5B levels in NHNE using a MUC5B ELISA kit. MUC5B levels were standardized according to the concentration of total protein for each sample. NHNE cells
were pretreated apically and basolaterally with PGD2 at the indicated concentrations for 24 h. E, NCI-H292 cells were treatedwith PGD2 (0.01, 0.1, and 1M) for
24h. Cell lysateswereharvested for ELISA. F, NCI-H292cellswere treatedwithPGD2 (1M) for 1, 3, 6, 12, and24h. ThemeanvaluesofMUC5BestimatedbyELISA
in cell lysates and its subgroups are expressed as ng of standard reactivity/ml of diluted resolubilized mucin sample. Significance was determined by the
Mann-WhitneyU test. Data are expressed as themean S.D. of triplicate cultures. At least three separate experimentswere performed for eachmeasurement.
C, untreated control; *, p 0.05 versus untreated control.
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of DNA in the immunoprecipitate, the abundance of genomic
DNA containing a promoter was determined through PCR
amplification using sequence-specific primers. Anti-rabbit IgG,
the negative control, did not yield any signals, indicating assay
specificity. Input chromatins were also used in these assays to
indicate that equal amounts of cell lysates were used. The ChIP
assays clearly showed that phosphorylated CREB bound
directly to theMUC5B promoter (953/753), and PD98059
treatment (ERK inhibitor) induced the dissociation of p-CREB
from the CRE of theMUC5B gene (Fig. 9, C and D). However,
no binding of CREB was detected regardless of PD98059 treat-
ment. We also obtained similar results in NHNE cells (data not
shown). Based on these results, we concluded that p-CREB pro-
tein is strongly bound to the chromatin regions of CRE binding
sites of theMUC5B promoter region with PGD2 treatment and
that CREB plays an important role in ERKMAPK signaling for
PGD2-induced MUC5B gene expression in airway epithelial
cells.
DISCUSSION
Mucus overproduction is related to several pathological fea-
tures of respiratory diseases such as asthma (3) and chronic
obstructive pulmonary disease (4). Excessive mucus in the air-
ways has been linked to an increase in the frequency and dura-
tion of infection, a decline in lung function, and increasedmor-
bidity andmortality in respiratory diseases. Mucus is produced
by goblet cells and submucosal glands in the large airways but
only by goblet cells in the small airways (2). In asthma and
chronic obstructive pulmonary disease patients, the major
mucin components of airway mucus secretions are MUC5AC
andMUC5B, both of which contribute to the viscoelastic prop-
erties of the mucus. However, the molecular mechanisms
underlying the up-regulation ofMUC5B gene expression due to
inflammatory stimuli remains poorly understood. Here, we
investigated the mechanism of MUC5B gene expression up-
regulation by PGD2 in airway epithelial cells.
Prostaglandins are among the major mediators of airway
inflammation and include human airway trypsin (43) and reac-
tive oxygen species (7), all of which increaseMUC5AC expres-
sion in vitro. PGD2 levels exhibit marked changes in various
pathological conditions such as asthma (16) and inflammatory
bowel disease (44).However, an increase in PGD2 level can have
either deleterious or protective effects. In this study we
observed H-PGDS and PGD2 expressions in nasal polyp tissue
and normal mucosa. Because the levels of PGD2 and H-PGDS
were much greater in nasal polyp tissue, we sought to ascertain
whether an increased level of PGD2 might lead to increased
MUC5B gene expression. We used PGD2 as a stimulant in air-
way epithelial cells, which led to an increase inMUC5B expres-
sion in airway epithelial cells in a time- and dose-dependent
manner.
One of the PGD2 receptors, DP1, was expressed in nasal
mucosa in epithelial goblet cells, serous glands, vascular endo-
thelium, epithelium, and in some of the infiltrating inflamma-
tory cells including eosinophils (45). We found that H-PGDS
andDP1were highly expressed in human primary nasal epithe-
lial cells. CRTH2 was also expressed, but only weakly. Thus,
PGD2 is likely involved inmultiple aspects of allergic inflamma-
tion via its dual receptor systems, DP1 and CRTH2, and seems
to be an important mediator in allergic diseases.
Recently, VanHecken et al. (46) reported that aDP1 receptor
antagonist, MK-0524, potently inhibits PGD2-induced nasal
blockage. In the present study we also demonstrated that
MUC5B gene expression was induced by PGD2 in airway epi-
thelial cells and that this induction could be completely sup-
pressed by the DP1 receptor antagonist, S-5751. These findings
suggest that PGD2 acts as a key factor ofMUC5B gene expres-
sion via the DP1 receptor in human airway epithelial cells.
We also showed that ERK MAPK/RSK1/CREB activation
was required for PGD2-inducedMUC5B gene expression. Sev-
eral studies have demonstrated that multiple MAP kinases are
involved in signal transduction pathways downstream of a vari-
ety of inflammatory mediators (47). Transcription of specific
genes is induced by the phosphorylation and activation of var-
ious transcription factors (48); however, little is known about
the specific effect of PGD2 on human airway epithelial cells.
Thus, we examined the role of MAP kinases in PGD2-depen-
dent signal transduction systems. Our previous work on
MUC5AC gene expression showed that cytokines such as inter-
FIGURE 4.DP1 is required for PGD2-inducedMUC5B gene expression in NCI-H292 cells. A, cells were treated with S5751 (DP1 antagonist, final concentra-
tion 0.01–10M) for 1 hbefore stimulationwith 1MPGD2. B, cellswere treatedwithOC0459 (CRTH2 antagonist, final concentration 0.01–10M) for 1 hbefore
stimulation with 1 M PGD2. Cells were subsequently stimulated with 1 M PGD2 for 24 h. MUC5B expression relative to that of 2M was determined using
real-time quantitative RT-PCR. Values represent themean S.D. The results represent three independent experiments. C, untreated control; *, p 0.05 versus
untreated control; **, p 0.001 versus PGD2 treatment alone.
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leukin-1 and tumor necrosis factor- activate at least two
MAP kinases, ERK and p38 MAPK (14). These findings also
suggest that ERK MAPK may be an important signaling mole-
cule inmucin gene expression, although themolecules involved
in the signaling of ERKMAP kinase for PGD2-inducedMUC5B
gene expression have yet to be identified.
One substrate of ERKs is RSKs. Upon activation, both ERKs
andRSKs translocate to thenucleus,whereRSKs canphosphor-
ylate CREB at Ser-133 (39). We have previously shown that
RSK1 and CREB are important downstream mediators of ERK
MAPK activation in estrogen receptor-induced MUC5B
expression (30). However, E2 (estradiol) does not directly bind
to the DP1 receptor but triggers the signaling pathway by inter-
acting with ER  (estrogen receptor ). It is only that E2 and
PGD2 have commonmolecules (RSK1, CREB) that are involved
in ERK MAPK downstream signaling.
In addition, CREB is a known regulator of the expressions of
the mucin genes MUC2, MUC5AC, and MUC5B on the p15
arm of chromosome 11 (11p15) (49). Recently, Koo and co-
workers (50) reported that CREB activation is required for
FIGURE 5.PGD2 inducesMUC5Bgene expression via ERKMAPK signaling. A, confluent cells were treatedwith PGD2 (1M) for 5, 10, 20, 30, and 60min, and
cell lysates were harvested for Western blot analysis. B, quantitation of the p-ERK/ERK ratio is shown. Representative Western blots using phospho-specific
antibodies show transient activation of ERK1/2, with amaximumeffect at 5min. ERK1/2, total ERK1/2. C, cells were pretreated for 1 hwith PD98059 (30M) and
stimulated for 5minwith PGD2 (1M) before collection of cell lysates forWestern blot analysis.D, confluent cells were pretreated for 1 hwith PD98059 (30M)
and stimulated for 24hwithPGD2 (1M)before collectionof total RNA for real-timequantitativeRT-PCR. E, after transfectionwith siERK1 (40nM), siERK2 (40nM),
or siRNA-negative control (40 nM), cells were stimulatedwith PGD2 (1M) for 5min followed by analysis of proteins usingWestern blotting. F, transfected cells
were stimulated with PGD2 (1 M) for 24 h before the collection of total RNA for real-time quantitative RT-PCR.MUC5B expression relative to that of 2M was
determined using real-time quantitative PCR. The figures are representative of at least three independent experiments. Data are expressed as themean S.D.
C, untreated control; *, p 0.05 versus PGD2 treatment alone.
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PGF2-inducedMUC5AC overproduction. Activation of CREB
plays a critical role in the signaling of inflammatory prostaglan-
dins. We have now investigated whether RSK1 can be directly
interaction with CREB in NCI-H292 cells. The interaction
between RSK1 and CREBwas significantly amplified in nucleus
by PGD2 treatment. However, inhibition of ERK MAPK path-
way greatly decreased the interaction of RSK1 and CREB. Our
results indicate that CREB activation is involved in the down-
stream signaling of ERK MAPK and RSK1 for PGD2-induced
MUC5B gene expression.
Like cAMP, Ca2 functions as a second messenger in a large
number of cellular processes (51). It is well established that
transient Ca2 fluxes regulate gene transcription and expres-
sion (52). Furthermore, generation of Ca2 fluxes by intact bac-
teria and flagella stimulates transcription of the NF-B-depen-
dent genes, MUC2 and IL-8 (53, 54). In airway epithelial cells,
FIGURE 6. DP1 is essential for PGD2-induced MUC5B expression through ERK signaling in NCI-H292 cells. A, cells were transiently transfected with
constructs expressing siRNA for DP1, CRTH2, DP1 DP2, or control siRNA. Cells were serum-starved and treated with 1 M PGD2 for 5 min, after which cell
lysateswere harvested forWestern blot analysiswith anti-ERK1/2. B, cells were serum-starved and treatedwith 1MPGD2 for 24 h, afterwhich cell lysateswere
harvested for real-time quantitative RT-PCR.MUC5B expression was determined relative to that of 2M using real-time quantitative PCR. C, untreated control;
*, p 0.05 versus PGD2 treatment alone.
FIGURE 7.RSK1 is essential for PGD2-inducedMUC5Bgene expression. A, confluent and quiescent cells were stimulatedwith PGD2 (1M) in a time-depen-
dent manner for up to 1 h followed by harvesting of cell lysates and Western blot analysis using anti-phospho-RSK1. -Actin served as an internal control.
B, quantitation of the p-ERK/ERK ratio is shown. The results of Western blot analyses are representative of three separate experiments. C, cells were transiently
transfectedwith RSK1 siRNA constructs. Transfected cells were serum-starved overnight before treatment with PGD2 (1M) for 30min, after which cell lysates
were harvested for Western blot analysis using specific antibodies. D, 24 h after transfection, cells were treated with PGD2 (1 M) and harvested for real time
quantitative RT-PCR.MUC5B expressionwasdetermined relative to2Mby real-timequantitative PCR. Figures represent three independent experiments. Data
are expressed as mean S.D. C, untreated control; *, p 0.05 versus PGD2 treatment alone.
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Ca2 fluxes travel from cell to cell and can also serve to amplify
Ca2-activated proinflammatory signals (55). In hippocampal
neurons, coupling of Ca2 influx and intracellular Ca2mobi-
lization pathways to CREB activation has been observed (56).
However, although astrocytes are activated by cAMP, they
lack the intracellular Ca2 signaling cascades required to
induce CREB-dependent gene transcription (41). This can be
explained by the report that CREB-dependent genes may also
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be activated by the MAPK and phosphoinositide 3-kinase sig-
naling pathways independent of Ca2 signaling (57). Likewise,
Shaywitz and Greenberg (58) have demonstrated that a variety
of kinase signaling pathways can differentially contribute to
Ca2 influx-mediated phosphorylation of CREB in pheochro-
mocytoma (PC12) cells. Notably, a recent paper reported that
treatment of human NK cells with PGD2 does not directly
increase intracellular Ca2 (59). Our data showed that PGD2
does not induce changes in the intracellular Ca2 content in
NCI-H292 cells, and we observed similar results in both
BEAS-2B and A549 cells. Together, these findings suggest that
cAMP may not be involved in Ca2-signaling responses,
depending on the type, whichmay reflect differentmechanisms
of Ca2 signaling.
CREB activation requires phosphorylation at Ser-133 to
promote formation of an active transcriptional complex that
includes recruitment of CREB-binding protein (CBP), p300,
and other transcriptional co-activators to CREs in the pro-
moters of target genes (60, 61). Another study (62) has
revealed that co-transfection of Sp1 with fragment 1896
(956/1) of the MUC5B promoter leads to an increase in
MUC5B expression in LS173T and Caco-2 cells, suggesting
that Sp1 may be another important transcription factor in
MUC5B gene expression. In addition, Choi et al. (30)
reported that CRE sites play an important role in 17-estra-
diol-induced MUC5B gene expression. The results of our
study show that independent point mutations of each CRE
site (921 to 914 and 900 to 893) in the MUC5B pro-
moter resulted in significant suppression of luciferase activ-
ity in NCI-H292 cells, indicating that both of these sites were
critical for PGD2-induced MUC5B gene expression. The
region (956/753) of MUC5B promoter was involved in
the response to PGD2, and activation of CREB was important
for MUC5B gene expression. We found that the PGD2-in-
duced phosphorylation of CREB had DNA binding and tran-
scriptional activities in the956/753 region. These results
suggest that both the CRE motif and activation of the CREB
signaling pathway are important in the up-regulation of
MUC5B gene expression by inflammatory mediators.
In conclusion, our data indicate that H-PGDS was highly
expressed in human nasal polyp tissues compared with that in
human normal nasal mucosa and that PGD2 was also increased
in human nasal polyp tissues. We found that one of the PGD2
receptors, DP1, was expressed in human primary nasal epithe-
lial cells, whereas the CRTH2 receptor was barely detectable.
Our data demonstrated that PGD2 induces MUC5B gene
expression in airway epithelial cells through the DP1 receptor.
Consistently, the DP1 antagonist S5751 significantly sup-
pressed PGD2-inducedMUC5B expression, whereas a CRTH2
antagonist did not. Furthermore, the activation of the ERK
MAPK/RSK1/CREB signaling pathway, but not intracellular
Ca2, was shown to be involved in PGD2-inducedMUC5B gene
expression. We also showed that RSK1 can interact directly
with CREB. Two CRE sites in the MUC5B promoter (921 to
914 and 900 to 893) appeared to play a vital role in
MUC5B expression in NCI-H292 cells. In addition, the activa-
FIGURE8.CREBmediatesPGD2-inducedMUC5Bgeneexpression independentof Ca
2 signaling.A, confluent andquiescent cellswere treatedwith PGD2
(1M) for 5, 10, 20, 30, and 60min, and cell lysateswere processed forWestern blot analysis using phospho-specific antibodies.-Actinwas used as an internal
control. B, quantitation of the p-CREB/CREB ratio is shown. The results of Western blot analyses are representative of three separate experiments. C, cells were
transfected with siCREB (40 nM) or siRNA-negative control (40 nM) and stimulated with PGD2 (1 M) for 10 min before Western blot analysis. D, cells were
serum-starved overnight, stimulated with PGD2 (1M) for 24 h, and analyzed using real time quantitative RT-PCR.MUC5B expression was determined relative
to that of 2M using real-time quantitative PCR. The figures are representative of three independent experiments. Data are expressed as the mean  S.D.
C, untreated control; *, p 0.05 versus PGD2 treatment alone. E, fluorescence images are shown to indicate interaction between two proteins. Staining with
primary anti-CREB goat polyclonal and anti-RSK1 rabbit polyclonal antibodies was followed by species-specific secondary antibodies with PLA probes. PLA
signaling (red dots) was detected inNCI-H292 cells using confocalmicroscopy (60). F, cells were serum-starved overnight and then treatedwith the indicated
concentrations of PGD2 for 1 h, after which cAMP production was measured. The values shown are the means S.D. of experiments performed in triplicate.
G, shown are fluorescence changes in response to PGD2 inNCI-H292 cells (10M). PGD2 inDMSOwas added to Fluo-2/AM-labeled cells (arrow 1), andATP (100
M)was added after 8min (arrow 2). Themeanbasal level of [Ca2]iwasmeasured for 1min before any treatment. Blue areas represent basal [Ca
2]i, and green
and red areas represent an increase frombase line. [Ca2]i versus time is shown for 10 cells (left).Colored lines show the trace of [Ca
2]imobilization in individual
cells (right). Results are representative of two independent experiments.
FIGURE 8—continued
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FIGURE 9. PGD2 enhances MUC5B promoter activity via cis-acting CRE regulatory motifs. A, cells were transiently transfected with various MUC5B
promoter luciferase reporter constructs and stimulatedwith PGD2 (1M) for 24 h. Luciferase activity wasmeasured in PGD2-treated and untreated cells. *, p
0.05 versus 530/92 reporter construct. B, cells were transfected with MUC5B promoter constructs containing mutated CRE sites as indicated. Cells were
treatedwith PGD2 (1M) for 24 h and then harvested. The luciferase activities shownhave been corrected for transfection efficiency using the-galactosidase
activity of the cell lysates. Data are expressed as themean S.D. of experiments performed in triplicate cultures. *, p 0.05 versuswild-type treatedwith PGD2
(1 M). C, cells were stimulated with PGD2 (1 M) for 20 min. Cross-linked protein-DNA complexes were immunoprecipitated using CREB antibody or normal
rabbit IgG that either amplified the CREB binding flanking region in MUC5B promoter (CRE site) or a region farther upstream that did not contain a CREB-
binding site (Non-CRE site). The immunoprecipitated chromatinwas analyzedwith PCRusingprimers specific to the indicated site. Input chromatin represents
a portion of the sonicated chromatin before immunoprecipitation. Control IgG (C), goat anti-rabbit IgG (negative control for ChIP).D, the results were analyzed
using real-time PCR and are shown as the percentage of input. The results are shown as means S.D. calculated from three independent experiments.
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tion of CREB is an important factor of cellular processes, indi-
cating that that CREs in the MUC5B promoter might play an
active role in these processes through their binding with CREB.
Taken together, these observations provide new insights into
the signaling mechanism ofMUC5B gene expression in airway
epithelial cells.
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